JPRN-UMIN000010051
Completed
未知
Combined efficacy of DPP-4 inhibitor in type 2 diabetic patients in the medical treatment of Sulfonylurea - Combined efficacy of DPP-4 inhibitor in type 2 diabetic patients in the medical treatment of Sulfonylurea
Osaka Saiseikai Noe Hospital0 sites120 target enrollmentFebruary 28, 2013
ConditionsType 2 diabetes
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Type 2 diabetes
- Sponsor
- Osaka Saiseikai Noe Hospital
- Enrollment
- 120
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The 55th Annual Meeting of the Japan Diabetes Society The 56th Annual Meeting of the Japan Diabetes Society
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with type 1 diabetes Patients with a history of severe ketosis, diabetic coma or pre\-coma within the past six months Patients with severe infection, before and after surgery, or severe trauma Patients with moderate renal impairment or more(serum creatinine level:1\.5mg/dl or more(male),1\.3mg/dl or more(female)) Patients in the insulin therapy, rapid insulin secretagogue, or alpha\-glucosidase inhibitor Patients with a planned pregnancy or likely to be pregnant or lactating patients, or pregnant patients Patients with a history of hypersensitivity to study drug
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Effects of DPP4 Inhibitor Versus SGLT2 InhibitorDiabetes Mellitus, Type 2Ischemic Heart DiseaseNCT03178591Chiang Mai University43
Recruiting
Not Applicable
Efficacy and safety of DPP-4 inhibitors in diabetic patients undergoing hemodialysisJPRN-UMIN000018445Keiai Hospital60
Completed
Phase 3
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2DType 2 DiabetesNCT01937598Michael A. Nauck16
Active, not recruiting
Not Applicable
ANTIDIABETIC EFFECTS OF ADDING A DPP-4 INHIBITOR (SITAGLIPTIN) TO PRE-EXISTING TREATMENT WITH AN INCRETIN MIMETIC (LIRAGLUTIDE) IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH METFORMITYPE 2 DIABETESMedDRA version: 16.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2013-001764-35-DEDiabeteszentrum Bad Lauterberg
Completed
Phase 4
DPP4 Inhibitor on Glycemic VariabilityDiabetes Mellitus, Type 2NCT04654676University Malaysia Sarawak12